NCT06543459

To Evaluate the Effect of Single Oral Dose of MY008211A Tablets on QTc Interval in Healthy Subjects

A Single-center, Randomized, Double-blind, Single Oral Dose, Placebo-controlled Study to Evaluate the Effect of MY008211A Tablets on QTc Interval in Healthy Chinese Adult Subjects

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (estimated)
• Sponsor: Wuhan Createrna Science and Technology Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

A Concentration-QT Interval Correction (C-QTc) study of MY008211A Tablets in Healthy Subjects

Detailed description

This is a single-center, randomized, double-blind, single oral dose, two groups, placebo-controlled study with 2 dose sequences preset

Conditions

• Paroxysmal Nocturnal Hemoglobinuria

Interventions

Type	Name	Description
DRUG	MY008211A tablets	Subjects of Group A receive MY008211A tablets on Day 1 of both Sequence, wash-out period is 6 Days at least.
DRUG	Placebo	Subjects of Group A receive placebo tablets on Day 1 of both Sequence, wash-out period is 6 Days at least.

Timeline

• Start date: 2024-08-10
• Primary completion: 2024-09-27
• Completion: 2024-12-13
• First posted: 2024-08-09
• Last updated: 2024-08-09

Locations

1 site across 1 country: China